In the OS2006 study, patients younger than 18 years were treated with a methotrexate‐based regimen (MTX), patients older than 25 years with a doxorubicin‐cisplatin‐ifosfamide–based regimen (API‐AI), whereas patients aged 18‐25 years received either API‐AI or MTX. We herein report the prespecified subgroup analysis of the outcome of 106 patients treated with API‐AI. Preoperative chemotherapy combined 3 API (doxorubicin‐ifosfamide‐cisplatin) and 2 AI (doxorubicin‐ifosfamide) courses. Postoperative...
Thu Jun 27, 2019 16:35
HPV FOCAL is a randomized control trial of cervical cancer screening. The intervention arm received baseline screening for high‐risk human papillomavirus (HPV) and the control arm received liquid‐based cytology (LBC) at baseline and 24‐months. Both arms received 48‐month exit HPV and LBC Co‐testing. Exit results are presented for per‐protocol eligible (PPE) screened women. Participants were PPE at exit if they had completed all screening and recommended follow‐up and had not been diagnosed with cervical...
Thu Jun 27, 2019 12:14
The olfactomedin 4 (OLFM4) gene has been analyzed as a tumor‐suppressor gene and a putative biomarker in many cancers. In this study, we analyzed the relationship of OLFM4 expression with clinicopathological features and with CpG site methylation in the OLFM4 gene promoter region in human primary prostate adenocarcinoma. OLFM4 protein expression was significantly reduced in prostate‐cancer tissue compared with adjacent normal tissue and was further significantly reduced in more advanced cancers....
Wed Jun 26, 2019 17:59
Tumor heterogeneity was associated with treatment outcome of metastatic cancers but few studies have examined whether tumor heterogeneity in circulating tumor DNA (ctDNA) can be used to predict treatment outcome. ctDNA analysis was performed in 37 HER2‐positive metastatic breast cancer patients treated with pyrotinib. Patients with high tumor heterogeneity had significantly worse PFS outcomes, with a median PFS of 30.0 weeks versus 60.0 weeks for patients with low tumor heterogeneity (hazard ratio...
Wed Jun 26, 2019 17:15
Adrenocortical carcinoma (ACC) is a rare malignancy whose risk factors are unclear. We explored the association of ACC risk with exposure to selected environmental factors, with a focus on cigarette smoking. We conducted a hospital‐based case‐control study at The University of Texas MD Anderson Cancer Center. Cases (N=432) patients with ACC treated at MD Anderson, and controls (N=1204) were healthy and genetically unrelated spouses of patients at MD Anderson who had cancers not associated with smoking....
Wed Jun 26, 2019 16:34
Stem cell chemo‐resistance is still challenging the efficacy of the front‐line temozolomide against glioblastoma. Novel therapies are urgently needed to fight those cells in order to control tumor relapse. Here, we report that anti‐O‐acetyl‐GD2 adjuvant immunotherapy controls glioma stem‐like cell‐driven chemo‐resistance. Using patient‐derived glioblastoma cells we found that glioma stem‐like cells over‐expressed O‐acetyl‐GD2. As a result, monoclonal antibody 8B6 immunotherapy significantly increased...
Wed Jun 26, 2019 15:09
Patients with idiopathic pulmonary fibrosis (IPF) have higher risk of developing lung cancer e.g. squamous cell carcinoma (SCC), and show poor prognosis, while the molecular basis has not been fully investigated. Here we conducted DNA methylome analysis of lung SCC using 20 SCC samples with/without IPF, and non‐cancerous lung tissue samples from smokers/non‐smokers, using Infinium HumanMethylation 450K array. SCC was clustered into low‐ and high‐methylation epigenotypes by hierarchical clustering...
Wed Jun 26, 2019 13:48
Despite its anticipated clinical potential, anti‐PD‐1 immunotherapy has only yielded poor outcomes in recent clinical trials for glioblastoma patients. Strategies combining anti‐PD‐1 antibody with other treatment modalities are being explored to alter the immunosuppressive microenvironment that appears to characterize these anti‐PD‐1‐insensitive tumors. Here, we evaluated whether introducing wild‐type p53 gene via a tumor‐targeting nanomedicine (termed SGT‐53) could provide immune stimulation and...
Wed Jun 26, 2019 13:24
Night shift work has been associated with breast and prostate cancer. Recent studies on breast cancer indicate that risk is highest in women with current night‐shift work and decreases with time since last night‐shift work. We re‐analysed data from the MCC‐Spain population based case‐control study to evaluate whether the attenuation shown for breast cancer by time since last exposure is also observed in prostate cancer. Incident histologically confirmed prostate cancer cases (n=1093) aged 27–85 were...
Mon Jun 24, 2019 13:44
Women with breast cancer are increasingly being cured of the disease but fatigue remains the most frequently reported symptom. The aims of this study were to identify distinct trajectories in 4 fatigue dimensions during 2 years after breast cancer surgery and to explore the demographic, clinical and personality characteristics associated with these profiles. We included women from the prospective longitudinal multicenter FATSEIN cohort in France. They completed the Multidimensional Fatigue Inventory...
Sat Jun 22, 2019 17:52
Latinos represent less than 1% of samples analyzed to date in genome‐wide association studies of cancer. The clinical value of genetic information in guiding personalized medicine in populations of non‐European ancestry will require additional discovery and risk locus characterization efforts across populations. In the present study, we performed a GWAS of PrCa in 2,820 Latino PrCa cases and 5,293 controls to search for novel PrCa risk loci and to examine the generalizability of known PrCa risk loci...
Fri Jun 21, 2019 20:08
Increased expression of GLI1, the main Hedgehog signalling pathway effector, is related to unfavourable prognosis and progressive disease of certain breast cancer subtypes. We used conditional transgenic mice induced to overexpress GLI1 in the mammary epithelium either alone or in combination with deletion of one Trp53 allele to address the role of elevated GLI1 expression in breast tumour initiation and progression. Induced GLI1 expression facilitates mammary gland tumour formation and this was...
Thu Jun 20, 2019 18:50
Although clinically associated with the progression of multiple cancers, the biological function of p21‐activated kinase 5 (PAK5) in breast cancer remains largely unknown. Here, we reveal that the PAK5‐aspartyl aminopeptidase (DNPEP)‐ ubiquitin‐specific protease 4 (USP4) axis is involved in breast cancer progression. We show that PAK5 interacts with and phosphorylates DNPEP at serine 119. Functionally, we demonstrate that DNPEP overexpression suppresses breast cancer cell proliferation and invasion...
Thu Jun 20, 2019 18:48
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,